{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T07:47:04Z","timestamp":1794988024503,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Migraine has been recognized as one of common diseases in the world whose current treatment options are not ideal. Lasmiditan, an oral 5-hydroxytryptamine (HT)<jats:sub>1F<\/jats:sub>receptor agonist, appears more promising for the acute treatment of migraine because of considerably better effect profiles with no severe adverse events (AEs). This review aimed to systematically evaluate the efficacy and safety of lasmiditan from the results of randomized controlled trials (RCTs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Cochrane Library, Embase were searched on lasmiditan for the acute treatment of migraine from inception of the databases to Feb 1, 2020. Pain free and pain relief, global impression (very much\/much better), and no\/mild disability at 2\u2009h in efficacy; total treatment-emergent adverse events (TEAEs), dizziness, nausea, fatigue, paraesthesia and somnolence in safety were extracted from the included studies. A systematic review and meta-analysis was performed using Review Manager Software version 5.3 (RevMan 5.3).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four RCTs with a total of 4960 subjects met our inclusion criteria. The overall effect estimate showed that lasmiditan was significantly superior to placebo in terms of pain free (RR 1.71, 95% CI 1.55\u20131.87), pain relief (RR 1.40, 95% CI 1.33\u20131.47), global impression (very much\/much better) (RR 1.55, 95% CI 1.44\u20131.67), and no\/mild disability (RR 1.15, 95% CI 1.10\u20131.20) at 2\u2009h. For the safety, significant number of patients experienced TEAEs with lasmiditan than with placebo (RR 2.77, 95% CI 2.53\u20133.03), most TEAEs were central nervous system (CNS)-related and included dizziness (RR 5.81, 95% CI 4.72\u20137.14), nausea (RR 2.58, 95% CI 1.87\u20133.57), fatigue (RR 5.38, 95% CI 3.78\u20137.66), paraesthesia (RR 4.48, 95% CI 3.33\u20136.02), and somnolence (RR 2.82, 95% CI 2.18\u20133.66).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis suggests that lasmiditan is effective for the acute treatment of migraine with a higher incidence of CNS-related adverse reactions compared with placebo. Long-term, open-label, multi-dose trials are required to verify the current findings.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-020-01138-x","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:02:50Z","timestamp":1591383770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Min","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"10100","key":"1138_CR1","first-page":"1211","volume":"390","author":"GBD","year":"2016","unstructured":"GBD (2016) Disease and injury incidence and prevalence collaborators (2017) global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390(10100):1211\u20131259","journal-title":"Lancet"},{"issue":"02","key":"1138_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-0038-1647245","volume":"38","author":"D Saylor","year":"2018","unstructured":"Saylor D, Steiner T (2018) The global burden of headache. Semin Neurol 38(02):182\u2013190","journal-title":"Semin Neurol"},{"issue":"1","key":"1138_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-015-0544-2","volume":"16","author":"TJ Steiner","year":"2015","unstructured":"Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P (2015) Headache disorders are third cause of disability worldwide. J Headache Pain 16(1):58","journal-title":"J Headache Pain"},{"issue":"2","key":"1138_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/13543784.2017.1280457","volume":"26","author":"M Capi","year":"2017","unstructured":"Capi M, de Andr\u00e9s F, Lionetto L, Gentile G, Cipolla F, Negro A et al (2017) Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs 26(2):227\u2013234","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1138_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s40064-016-2211-8","volume":"5","author":"F Antonaci","year":"2016","unstructured":"Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A (2016) Recent advances in migraine therapy. Springerplus 5(1):637","journal-title":"Springerplus"},{"issue":"7","key":"1138_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1177\/0333102409354390","volume":"30","author":"F Sheftell","year":"2010","unstructured":"Sheftell F, Almas M, Weeks R, Mathew NT, Pitman V, Lipton RB (2010) Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia 30(7):838\u2013846","journal-title":"Cephalalgia"},{"issue":"2","key":"1138_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1526-4610.2005.05031.x","volume":"45","author":"DW Dodick","year":"2005","unstructured":"Dodick DW (2005) Triptan nonresponder studies: implications for clinical practice. Headache 45(2):156\u2013162","journal-title":"Headache"},{"issue":"10","key":"1138_CR8","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30(10):1159\u20131169","journal-title":"Cephalalgia"},{"issue":"18","key":"1138_CR9","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN (2019) Lasmiditan: first approval. Drugs 79(18):1989\u20131996","journal-title":"Drugs"},{"issue":"Suppl 1","key":"1138_CR10","first-page":"9","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders (second edition). Cephalalgia 24(Suppl 1):9\u2013160","journal-title":"Cephalalgia"},{"issue":"9","key":"1138_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629\u2013808","journal-title":"Cephalalgia"},{"key":"1138_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"1138_CR13","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG (2008) Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Wiley.","DOI":"10.1002\/9780470712184"},{"issue":"11","key":"1138_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"3","key":"1138_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E (2015) Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid-Based Healthc 13(3):196\u2013207","journal-title":"Int J Evid-Based Healthc"},{"issue":"10","key":"1138_CR16","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"MD Ferrari","year":"2010","unstructured":"Ferrari MD, F\u00e4rkkil\u00e4 M, Reuter U, Pilgrim A, Davis C, Krauss M et al (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan \u2013 a randomised proof-of-concept trial. Cephalalgia 30(10):1170\u20131178","journal-title":"Cephalalgia"},{"issue":"5","key":"1138_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","unstructured":"F\u00e4rkkil\u00e4 M, Diener HC, G\u00e9raud G, L\u00e1inez M, Schoenen J, Harner N et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11(5):405\u2013413","journal-title":"Lancet Neurol"},{"issue":"24","key":"1138_CR18","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91(24):e2222\u2013e2232","journal-title":"Neurology"},{"issue":"7","key":"1138_CR19","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7):1894\u20131904","journal-title":"Brain"},{"issue":"4\u20135","key":"1138_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0028-3908(97)00020-8","volume":"36","author":"N Adham","year":"1997","unstructured":"Adham N, Bard JA, Zgombick JM, Durkin MM, Kucharewicz S, Weinshank RL et al (1997) Cloning and characterization of the Guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology 36(4\u20135):569\u2013576","journal-title":"Neuropharmacology"},{"issue":"9289","key":"1138_CR21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","volume":"358","author":"DJ Goldstein","year":"2001","unstructured":"Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Ferrari MD (2001) Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358(9289):1230\u20131234","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1138_CR22","doi-asserted-by":"publisher","first-page":"s71","DOI":"10.1185\/0300799039117001","volume":"17","author":"NM Ramadan","year":"2001","unstructured":"Ramadan NM (2001) Acute treatments: some blind alleys. Curr Med Res Opin 17(Suppl 1):s71\u2013s80","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1138_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10194-012-0428-7","volume":"13","author":"PC Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen PC, Olesen J (2012) The 5-HT1Freceptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 13(4):271\u2013275","journal-title":"J Headache Pain"},{"issue":"1","key":"1138_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1526-4610.1981.hed2101001.x","volume":"60","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Krege JH, Hundemer HP, Berg PH, Khanna R, Ossipov MH et al (2020) Issues impacting adverse event frequency and severity: differences between randomized phase 2 and phase 3 clinical trials for Lasmiditan. Headache 60(1):1\u201313","journal-title":"Headache"},{"issue":"13","key":"1138_CR25","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1080\/14656566.2017.1361406","volume":"18","author":"B Raffaelli","year":"2017","unstructured":"Raffaelli B, Israel H, Neeb L, Reuter U (2017) The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother 18(13):1744\u20137666","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"1138_CR26","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R et al (2019) Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39(11):1343\u20131357","journal-title":"Cephalalgia"},{"issue":"1","key":"1138_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0333102419889350","volume":"40","author":"K Knievel","year":"2020","unstructured":"Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH et al (2020) Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia 40(1):19\u201327","journal-title":"Cephalalgia"},{"issue":"8","key":"1138_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0333102419855080","volume":"39","author":"JH Krege","year":"2019","unstructured":"Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J et al (2019) Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia 39(8):957\u2013966","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01138-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01138-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01138-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T21:25:25Z","timestamp":1666819525000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01138-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01138-x","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}